Robin Smith, the CEO of NBS, got some very bad advice. She did the R/S to attract institutional investors supposedly. She just did a secondary a couple of months ago and did not need cash again until late in the year. The stock was really coming alive and then she killed it on very bad advice. R/S is the worst thing a penny stock can do, last resort type of thing it should be, not to attract mutual funds, etc. Don't think ZLCS is that stupid.
Corrigan is in a bit of a pickle currently. When he took over as CEO, he went to Wall Street and did alot of work in rebuilding the company image and attracting investors. They changed the company name and tried to put branding around it. He hasn't really been successful with the investment community so he needs to make sure his future press releases are positive. The company spent so much money on the arthritis treatment that if Sanofi continues with it then it will put the company back on the map. Their revenue source happened through acquisition. The question mark hangs over current R&D.